Arovella Therapeutics Limited - Advancements in CAR-iNKT Cell Therapy for Pancreatic and Gastric Cancer
Arovella Therapeutics Limited (ASX: ALA) has achieved significant progress in its CAR-iNKT cell therapy platform. The company has confirmed the efficacy of its CLDN18.2-targeting chimeric antigen receptor (CAR) integrated with invariant natural killer T (iNKT) cells, specifically for targeting pancreatic and gastric cancer cells. They’re in vitro studies demonstrate that CLDN18.2-CAR-iNKT cells exhibit potent anti-cancer activity against these cancers, with the addition of IL-12-TM armouring enhancing the cells' efficacy.
In tests, the armoured CAR-iNKT cells effectively eliminated over 97% of pancreatic and 82% of gastric cancer cells after multiple rounds of exposure. This is a key milestone for Arovella, highlighting the durability and resilience of their novel therapeutic approach. The company aims to extend its pipeline to address other solid tumours and is now moving forward with animal model studies for these cancers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Arovella Therapeutics Limited - Advancements in CAR-iNKT Cell Therapy for Pancreatic and Gastric Cancer
Arovella Therapeutics Limited (ASX: ALA) has achieved significant progress in its CAR-iNKT cell therapy platform. The company has confirmed the efficacy of its CLDN18.2-targeting chimeric antigen receptor (CAR) integrated with invariant natural killer T (iNKT) cells, specifically for targeting pancreatic and gastric cancer cells. They’re in vitro studies demonstrate that CLDN18.2-CAR-iNKT cells exhibit potent anti-cancer activity against these cancers, with the addition of IL-12-TM armouring enhancing the cells' efficacy.
In tests, the armoured CAR-iNKT cells effectively eliminated over 97% of pancreatic and 82% of gastric cancer cells after multiple rounds of exposure. This is a key milestone for Arovella, highlighting the durability and resilience of their novel therapeutic approach. The company aims to extend its pipeline to address other solid tumours and is now moving forward with animal model studies for these cancers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au